Mycobacterium Bovis Bacillus Calmette-Guérin-induced Macrophage Cytotoxicity Against Bladder Cancer Cells

Overview

Journal Clin Dev Immunol

Specialty Allergy & Immunology

Date 2010 Sep 24

PMID 20862387

Citations 26

Authors

Yi Luo

Matthew J Knudson

Affiliations

Soon will be listed here.

Abstract

Many details of the molecular and cellular mechanisms involved in Mycobacterium bovis bacillus Calmette-Guérin (BCG) immunotherapy of bladder cancer have been discovered in the past decades. However, information on a potential role for macrophage cytotoxicity as an effector mechanism is limited. Macrophages play pivotal roles in the host innate immunity and serve as a first line of defense in mycobacterial infection. In addition to their function as professional antigen-presenting cells, the tumoricidal activity of macrophages has also been studied with considerable interest. Studies have shown that activated macrophages are potent in killing malignant cells of various tissue origins. This review summarizes the current understanding of the BCG-induced macrophage cytotoxicity toward bladder cancer cells with an intention to inspire investigation on this important but underdeveloped research field.

Citing Articles

Revitalizing Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches.

Lv M, Shang S, Liu K, Wang Y, Xu P, Song H Pharmaceutics. 2024; 16(8).

PMID: 39204412 PMC: 11359013. DOI: 10.3390/pharmaceutics16081067.

Efficacy of Bacillus Calmette-Guérin in Cancer Prevention and Its Putative Mechanisms.

Gupta S, Yadav S, Kumar P J Cancer Prev. 2024; 29(1):6-15.

PMID: 38567111 PMC: 10982520. DOI: 10.15430/JCP.23.036.

The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer.

Kustrimovic N, Bilato G, Mortara L, Baci D Int J Mol Sci. 2024; 25(3).

PMID: 38339010 PMC: 10855347. DOI: 10.3390/ijms25031732.

The Urinary Microbiome: Role in Bladder Cancer and Treatment.

Friedrich V, Choi H Diagnostics (Basel). 2022; 12(9).

PMID: 36140470 PMC: 9497549. DOI: 10.3390/diagnostics12092068.

Novel molecules as the emerging trends in cancer treatment: an update.

Sekar P, Ravitchandirane R, Khanam S, Muniraj N, Cassinadane A Med Oncol. 2022; 39(2):20.

PMID: 34982273 DOI: 10.1007/s12032-021-01615-6.

References

Bohle A, Nowc C, Ulmer A, Musehold J, Gerdes J, Hofstetter A . Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol. 1990; 144(1):59-64. DOI: 10.1016/s0022-5347(17)39366-7. View

Umansky V, Schirrmacher V . Nitric oxide-induced apoptosis in tumor cells. Adv Cancer Res. 2001; 82:107-31. DOI: 10.1016/s0065-230x(01)82004-2. View

Huguenin S, Vacherot F, Fleury-Feith J, Riffaud J, Chopin D, Bolla M . Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines. Cancer Lett. 2005; 218(2):163-70. DOI: 10.1016/j.canlet.2004.06.003. View

Petricevich V, Alves R . Role of cytokines and nitric oxide in the induction of tuberculostatic macrophage functions. Mediators Inflamm. 2001; 9(6):261-9. PMC: 1781774. DOI: 10.1080/09629350020027564. View

Horinaga M, Harsch K, Fukuyama R, Heston W, Larchian W . Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology. 2005; 66(2):461-6. DOI: 10.1016/j.urology.2005.03.052. View

Klostergaard J, LEROUX M, Hung M . Cellular models of macrophage tumoricidal effector mechanisms in vitro. Characterization of cytolytic responses to tumor necrosis factor and nitric oxide pathways in vitro. J Immunol. 1991; 147(8):2802-8. View

Kindler V, Sappino A, Grau G, Piguet P, Vassalli P . The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989; 56(5):731-40. DOI: 10.1016/0092-8674(89)90676-4. View

de Boer E, De Jong W, van der Meijden A, Steerenberg P, Witjes J, Vegt P . Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother. 1991; 33(6):411-6. PMC: 11038680. DOI: 10.1007/BF01741603. View

Alexandroff A, Jackson A, ODonnell M, JAMES K . BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999; 353(9165):1689-94. DOI: 10.1016/S0140-6736(98)07422-4. View

10.

Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek C . Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells. Clin Cancer Res. 2000; 6(9):3729-38. View

11.

Chomarat P, Banchereau J, Davoust J, Palucka A . IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 2001; 1(6):510-4. DOI: 10.1038/82763. View

12.

Bogdan C, Vodovotz Y, Nathan C . Macrophage deactivation by interleukin 10. J Exp Med. 1991; 174(6):1549-55. PMC: 2119047. DOI: 10.1084/jem.174.6.1549. View

13.

Bohle A, Gerdes J, Ulmer A, Hofstetter A, Flad H . Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol. 1990; 144(1):53-8. DOI: 10.1016/s0022-5347(17)39365-5. View

14.

Rosevear H, Lightfoot A, ODonnell M, Griffith T . The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer Metastasis Rev. 2009; 28(3-4):345-53. DOI: 10.1007/s10555-009-9195-6. View

15.

Luo Y, Chen X, ODonnell M . Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol. 2007; 147(2):370-8. PMC: 1810474. DOI: 10.1111/j.1365-2249.2006.03288.x. View

16.

Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Stockle M, Jocham D . Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 2006; 66(16):8250-7. DOI: 10.1158/0008-5472.CAN-06-1416. View

17.

Morcos E, Jansson O, Adolfsson J, Kratz G, Wiklund N . Endogenously formed nitric oxide modulates cell growth in bladder cancer cell lines. Urology. 1999; 53(6):1252-7. DOI: 10.1016/s0090-4295(99)00033-3. View

18.

de Boer E, De Jong W, van der Meijden A, Steerenberg P, Witjes F, Vegt P . Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res. 1991; 19(1):45-50. DOI: 10.1007/BF00294021. View

19.

Higuchi T, Shimizu M, Owaki A, Takahashi M, Shinya E, Nishimura T . A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth. Cancer Immunol Immunother. 2009; 58(8):1245-55. PMC: 11030957. DOI: 10.1007/s00262-008-0643-x. View

20.

Cenci E, Romani L, Mencacci A, Spaccapelo R, Schiaffella E, Puccetti P . Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur J Immunol. 1993; 23(5):1034-8. DOI: 10.1002/eji.1830230508. View